Martin Hemmerling

AstraZeneca (Sweden)

Papers

1

Total Citations

54

H-Index

1

About

Martin Hemmerling is a leading researcher in the field of dendrimer-based drug delivery, with a particular focus on engineering precise nanocarriers for nucleic acid therapeutics. His work centers on the rational design of synthetic macromolecules—specifically PAMAM and poly(L-lysine) dendrimers—to overcome biological barriers for cytosolic delivery. Hemmerling’s most notable contribution is his development of systematic end-group chemistry modifications that dramatically improve the cytosolic delivery of mRNA, a critical challenge in gene therapy and vaccine development. His 2023 paper on this topic has already garnered 54 citations, reflecting its immediate impact on the field. By demonstrating how subtle chemical alterations can enhance cellular uptake and endosomal escape, Hemmerling has provided a foundational framework for designing next-generation dendrimer-based carriers. His work bridges synthetic chemistry and nanomedicine, offering scalable strategies for mRNA therapeutics. For students and researchers, Hemmerling’s research exemplifies how precise molecular engineering can solve real-world delivery problems, making him a key figure in advancing non-viral gene delivery systems.

Research Focus

Key Achievements

1
H-Index
1
Papers
54
Total Citations
54
Avg Citations/Paper
🏆 Most Cited Paper
Precise and systematic end group chemistry modifications on PAMAM and poly(l-lysine) dendrimers to improve cytosolic delivery of mRNA
54 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: AstraZeneca (Sweden)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago